ERBB2 and breast carcinoma: Critically, these data resembled our previous findings based on proteomic analysis of αVβ6 IACs in HER2+ breast cancer cells (Figs. 1 and 3) and highlight the importance of the interplay between the proinvasive receptor αVβ6 and trafficking pathways in patients with HER2+ breast cancer.